INVOKAMET XR Rx
Generic Name and Formulations:
Canagliflozin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 150mg/500mg, 150mg/1000mg; tabs.
Janssen Pharmaceuticals, Inc.
Indications for INVOKAMET XR:
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.
Limitations Of use:
Not for treating type 1 diabetes or diabetic ketoacidosis.
See full labeling. Individualize. Swallow whole. Take once daily with the morning meal; increase dose gradually as tolerated. Currently not treated with canagliflozin or metformin: initially two XR (50mg/500mg) tabs; if need additional glycemic control, may increase to canagliflozin 300mg once daily. Previously on canagliflozin and metformin: switch to two XR tabs on a mg/mg basis. Max daily dose: 300mg/2000mg. Moderate renal impairment (eGFR 45–<60mL/min/1.73m2): max canagliflozin 100mg once daily. Concomitant UGT inducers in patients with eGFR ≥60mL/min/1.73m2: consider increase to canagliflozin 300mg once daily; if eGFR 45–<60mL/min/1.73m2: consider other antihyperglycemics.
<18yrs: not established.
Moderate to severe renal impairment (eGFR <45mL/min/1.73m2), ESRD, or on dialysis. Metabolic acidosis, diabetic ketoacidosis.
Lactic acidosis. Lower limb amputation.
Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors), ≥65yrs of age, undergoing radiological contrast study, surgery and other procedures, hypoxic states, and excessive alcohol intake; discontinue if lactic acidosis occurs. Discontinue at time of, or prior to intravascular iodinated contrast imaging in patients with eGFR 45–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart therapy if renally stable. Increased risk of lower limb amputations; monitor for infection, new pain or tenderness, sores or ulcers in lower limbs, and discontinue if occur. Consider risk factors for amputation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers) before initiation. Correct volume depletion before initiating. Monitor for symptomatic hypotension in renal impairment (eGFR <60mL/min/1.73m2), elderly, low systolic BP, concomitant diuretics or drugs that interfere with the RAA system (eg, ACEIs, ARBs). Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Assess renal function prior to starting and periodically thereafter; more frequently in elderly or if eGFR <60mL/min/1.73m2. Risk of acute kidney injury in hypovolemia, chronic renal insufficiency, CHF, and concomitant drugs (eg, diuretics, ACEIs, ARBs, NSAIDs). Consider temporarily discontinuing in reduced oral intake or fluid losses; monitor for acute kidney injury; discontinue and treat if occurs. Monitor serum K+ levels in patients predisposed to hyperkalemia. Consider risk factors for bone fractures before initiation. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Discontinue if hypersensitivity reactions occur. Monitor for genital mycotic infections, UTIs, hematology (esp. serum Vit. B12), increases in LDL-C; treat if needed. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
Sodium-glucose co-transporter 2 (SGLT2) inhibitor + biguanide.
Concomitant cationic drugs that interfere with renal tubular transport systems (eg, ranolazine, vandetanib, dolutegravir, cimetidine) may increase metformin levels. Increased risk of lactic acidosis with topiramate, other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide, dichlorphenamide); monitor. Diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, sympathomimetics, nicotinic acid, CCBs, and isoniazid may cause hyperglycemia. Avoid excessive alcohol. Antagonized by UGT inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir): see Adults. Concomitant digoxin: monitor. Consider a lower dose of concomitant insulin/insulin secretagogue to reduce risk of hypoglycemia. May cause false (+) urine glucose tests or unreliable measurements of 1, 5-AG assay; use alternative methods to monitor glycemic control.
Female genital mycotic infections, UTI (may be serious), increased urination, GI upset, flatulence, asthenia, indigestion, abdominal discomfort, headache; lactic acidosis (rare), lower limb amputation, hypotension, ketoacidosis (may be fatal), acute kidney injury, hyperkalemia, hypoglycemia, increases in LDL-C, bone fractures, urosepsis, pyelonephritis.
Tabs, XR tabs—60
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking